ADC Therapeutics SA (ADCT) Tops Q3 EPS by 17c
Tweet
Share
E-mail
Get Alerts ADCT Hot Sheet
Join SI Premium – FREE
ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.19), $0.17 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.43 million versus the consensus estimate of $17.98 million.
For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- AI/ML Innovations plans $2M private placement on the CSE
- Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
